ParagonDx gets approval for warfarin sensitivity test

05/5/2008 | News & Observer (Raleigh, N.C.), The

The FDA has granted ParagonDx clearance to market a genetic test that can detect the sensitivity of heart attack and stroke patients to the blood thinner warfarin. The product, which is expected to be available in a few months, can cut the risk of excessive bleeding among patients taking warfarin.

View Full Article in:

News & Observer (Raleigh, N.C.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC